Current Advances in the Treatment of BRAF-Mutant MelanomaHima Patel(Kansas City University), Joan T. Garrett(University of Cincinnati Medical Center)CancersFebruary 19, 202010.3390/cancers12020482Cited by 172SaveCiteExport RISWatch citationsRelated PapersActivating HER3 mutations in breast cancer|Oncotarget|2018|36IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma|Cancers|2021|33HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers|PLoS ONE|2023|9RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells|Anti-Cancer Drugs|2023|6